Code

M13-101//2011-005393-32



Promoter

Janssen-Cilag International NV


Pathology and candidate patients

Hepatitis


Medical equipment

Dr. Moises Diago

Hospital Quirónsalud Valencia.



Study status

Active


Test product

TMC435 más interferón pegilado alfa 2a y ribavirina


Date CEIC

August 2, 2013


CEIC

Hospital Quirónsalud valencia



Contact

If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the cardiology team by sending an email to the address: info.valencia@quironsalud.es